EU projects promote personalised medicines for breast cancer

Published: 18-Nov-2014
Research & Development Pharmaceutical

EC stresses the value of the MINDACT trials


The European Commission (EC) has highlighted a series of European Union (EU)-funded research projects aimed at making breast cancer treatments more effective through personalised medicine approaches. Notably, the EC stressed the value of the MINDACT trials, whose results will be available in 2015, assessing how genomic analysis can help physicians better target chemotherapy. The work is associated with the EU’s TRANSBIG project, linking laboratory studies to medicine-based health treatment.

The Commission also highlighted the CareMore and CTCTRAP projects looking at how to test for tumour cells and DNA in blood to guide early treatments of breast cancer patients. And also the ASSURE project, tailoring breast cancer screening for women whose breasts are too dense for standard mammography.

The RATHER project is identifying novel treatments for women with triple-negative and invasive lobular breast cancer, while the MERIT project is developing treatments for triple-negative breast cancers using personalised RNA vaccines.

See more

You may also like

Research & Development

Compact process thermostat for efficient temperature control in the laboratory

Read more
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  3. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Manufacturing

Naobios and Sumagen sign exclusive partnership to develop HIV vaccine

Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Subscribe now